Please assess the completion status of the following clinical trial:

Trial Title: Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Postmenopausal women at increased risk for developing invasive breast cancer, who meet one of the following criteria:~  * At least 12 months since spontaneous menstrual bleeding~ * Prior documented hysterectomy and bilateral salpingo-oophorectomy~ * At least 55 years of age with prior hysterectomy with or without oophorectomy~ * Age 35 to 54 with a prior hysterectomy without oophorectomy OR with a status of ovaries unknown with documented follicle-stimulating hormone level demonstrating elevation in postmenopausal range~* Histologically confirmed lobular carcinoma in situ treated by local excision only OR a minimum projected 5 year probability of invasive breast cancer of at least 1.66%, using Breast Cancer Risk Assessment Profile~* No clinical evidence of malignancy on physical exam within the past 180 days~* No evidence of suspicious or malignant disease on bilateral mammogram within the past year~* No bilateral or unilateral prophylactic mastectomy~* No prior invasive breast cancer or intraductal carcinoma in situ~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 35 and over~Sex:~* Female~Menopausal status:~* See Disease Characteristics~Performance status:~* No restricted normal activity for a significant portion of each day~Life expectancy:~* At least 10 years~Hematopoietic:~* Granulocyte count at least 1,500/mm\^3~* Complete blood count and differential normal~* Platelet count normal~Hepatic:~* SGOT or SGPT normal~* Bilirubin normal~* Alkaline phosphatase normal~Renal:~* Creatinine normal~Cardiovascular:~* No cerebral vascular accident, transient ischemic attack, atrial fibrillation, or uncontrolled hypertension~* No deep vein thrombosis~Pulmonary:~* No pulmonary embolus~Other:~* No other prior malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No concurrent nonmalignant disease that would preclude administration of tamoxifen or raloxifene~* No clinical depression, psychiatric condition, or addictive disorder~* No uncontrolled diabetes~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* At least 3 months since prior estrogen or progesterone replacement therapy, oral contraceptives, androgens, luteinizing hormone-releasing hormone analogs, prolactin inhibitors, or antiandrogens~* At least 3 months since prior tamoxifen, raloxifene, or other selective estrogen-receptor modulators of less than 3 months duration~* Concurrent Estring allowed~Radiotherapy:~* No prior breast radiotherapy~Surgery:~* See Disease Characteristics~Other:~* No prior systemic adjuvant therapy for breast cancer~* No other participation in a cancer prevention or osteoporosis prevention study involving pharmacologic intervention(s)~  * NSABP-P-1 patients who received placebo are eligible~* No concurrent warfarin or cholestyramine~* Concurrent calcitonin or nonhormonal medication (e.g., cholecalciferol, fluoride, or bisphosphonates) allowed

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Tamoxifen and placebo
- Group 2 (Type: EXPERIMENTAL): Raloxifene and Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete